Helicobacter pylori infection
Conditions
Interventions
Patients from Changzhou (Han) :Vonoprazan 20mg twice daily + Amoxicillin 1000mg three times daily for 10 days
Qinghai (Han):Vonoprazan 20mg twice daily + Amoxicillin 1000mg three times daily for 10 days
Qinghai (Tibetan):Vonoprazan 20mg twice daily + Amoxicillin 1000mg three times daily for 10 days
Qinghai (Hui):Vonoprazan 20mg twice daily + Amoxicillin 1000mg three times daily for 10 days
Sponsors
Changzhou Wujin People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years, regardless of gender. 2. Of Han, Hui, or Tibetan ethnicity. 3. Positive for Helicobacter pylori (H. pylori) infection confirmed by a 13C- or 14C-urea breath test within one month. 4. Participants with a diagnosis of H. pylori-positive chronic gastritis confirmed by gastroscopy within three months, who meet the indications for H. pylori eradication as recommended by the Sixth National Consensus Report on the Management of H. pylori Infection, and are willing to undergo eradication therapy. 5. No history of prior H. pylori eradication treatment. 6. Provision of signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Participants with a known allergy to any of the drugs used in this study. 2. Use of Vonoprazan, PPIs, H2-receptor antagonists, antibiotics, bismuth agents, or probiotic preparations within one month prior to treatment initiation. 3. Women who are pregnant or breastfeeding, or participants planning a pregnancy during the study period. 4. Concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), adrenal corticosteroids, or anticoagulants during the study period. 5. Presence of severe concomitant diseases that may interfere with the study evaluation, including cardiac, pulmonary, hepatic, renal, metabolic, or psychiatric diseases, as well as malignant tumors. 6. History of previous gastric or esophageal surgery. 7. Inability to complete the required follow-up or presence of any other factors that may compromise adherence to the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance; | — |
Countries
China
Contacts
Public ContactPeipei Luo
Changzhou Wujin People's Hospital
Outcome results
None listed